Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | DLK1 | P80370 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854339 | 0.88 | KAT2B (0.32) | MAP3K12 | |
| SCHEMBL15739872 | 0.81 | KDM2B (0.35) | MAP3K12KDM2B | |
| SCHEMBL17308195 | 0.81 | KDM2B (0.35) | MAP3K12KDM2B | |
| SCHEMBL23337914 | 0.77 | MAP3K12 (0.33) | MAP3K12DLK1 | |
| SCHEMBL25046007 | 0.77 | MAP3K12 (0.33) | MAP3K12DLK1 | |
| SCHEMBL24854323 | 0.76 | KDM2B (0.30) | KDM2B | |
| SCHEMBL17660700 | 0.76 | LRRK2 (0.32) | MAP3K12DLK1 | |
| SCHEMBL24854802 | 0.75 | MAP3K12 (0.32) | MAP3K12 | |
| SCHEMBL24854340 | 0.74 | HRH3 (0.37) | — | |
| SCHEMBL19532028 | 0.74 | OPRM1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | MAP3K12 107/4885KDM2B 2165/4885DLK1 620/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | MAP3K12 107/4885KDM2B 2165/4885DLK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.